HC Wainwright & Co. Reiterates Buy on Cara Therapeutics, Maintains $3.6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a price target of $3.6.
May 15, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Cara Therapeutics and maintained a price target of $3.6.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100